Santiago Tofé
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Santiago Tofé has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Iñaki Argüelles
Endocrinology and Nutrition Department, Son Espases University Hospital, Palma, Spain
8 shared publications Vicente Pereg
Univ Hosp Son Espases, Dept Endocrinol, Palma De Mallorca 07120, Spain
6 shared publicationsElena Mena Ribas
4 shared publicationsGuillermo Serra Soler
4 shared publicationsVicente Pereg Macazaga
4 shared publicationsCristina Álvarez
Univ Hosp Son Espases, Dept Surg, Sect Endocrine Surg, Palma De Mallorca, Spain
3 shared publications
Latest Publications
- 7 September 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 287
Efficacy, safety and predictors of response to minimally invasive treatments of the thyroid: a prospective study
Purpose Minimally invasive techniques (MITs), including percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA), are effective non-surgical options for benign thyroid nodules (BTN). However, predictors of response and technical determinants remain incompletely defined. Methods We conducted a prospective single-center study including 120 BTNs (45 PEI, 75 RFA) treated between 2022 and 2025, with 12-month follow-up. The primary objective of this study was to identify clinical and procedural predictors of treatment response following MITs for BTNs. The primary outcome measure was the 12-month volume reduction ratio (VRR). Secondary endpoints included changes in cosmetic and symptomatic scores, thyroid function in autonomously functioning nodules (AFTN), and safety outcomes. Results Baseline mean nodule volume was 22.06 mL SD 14.52, cosmetic score 3.39 SD 0.93, and dysphagia score 3.33 SD 1.8. At 12 months, mean VRR was 84.24% overall, 95.9% after PEI, and 77.4% after RFA, achieving therapeutic success in 96.67% of cases (p < 0.001). In AFTN, MITs, comprising 3 predominantly cystic nodules treated with PEI and 10 solid nodules treated with RFA, achieved a mean VRR of 88.17%, with TSH increasing from 0.12 SD 0.13 to 2.17 SD 2.47 mIU/L; 76.9% of these patients were on antithyroid medication prior to ablation, all discontinued post-procedure. Baseline nodule volume independently predicted VRR (β = − 0.237; p = 0.014), while energy density (kcal/mL) predicted RFA efficacy (β = 1.416; p = 0.047). All adverse events were mild and transient, including local pain (27.5%), transient dysphonia (6.7%), and transient cough or vagal reaction. No permanent complications occurred. Conclusion PEI and RFA are safe and effective minimally invasive options for BTN, achieving durable volume reduction with improved clinical outcomes. Smaller nodules and higher energy delivery/ml predict optimal response.
- 7 September 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 287
Efficacy, safety and predictors of response to minimally invasive treatments of the thyroid: a prospective study
Purpose Minimally invasive techniques (MITs), including percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA), are effective non-surgical options for benign thyroid nodules (BTN). However, predictors of response and technical determinants remain incompletely defined. Methods We conducted a prospective single-center study including 120 BTNs (45 PEI, 75 RFA) treated between 2022 and 2025, with 12-month follow-up. The primary objective of this study was to identify clinical and procedural predictors of treatment response following MITs for BTNs. The primary outcome measure was the 12-month volume reduction ratio (VRR). Secondary endpoints included changes in cosmetic and symptomatic scores, thyroid function in autonomously functioning nodules (AFTN), and safety outcomes. Results Baseline mean nodule volume was 22.06 mL SD 14.52, cosmetic score 3.39 SD 0.93, and dysphagia score 3.33 SD 1.8. At 12 months, mean VRR was 84.24% overall, 95.9% after PEI, and 77.4% after RFA, achieving therapeutic success in 96.67% of cases (p < 0.001). In AFTN, MITs, comprising 3 predominantly cystic nodules treated with PEI and 10 solid nodules treated with RFA, achieved a mean VRR of 88.17%, with TSH increasing from 0.12 SD 0.13 to 2.17 SD 2.47 mIU/L; 76.9% of these patients were on antithyroid medication prior to ablation, all discontinued post-procedure. Baseline nodule volume independently predicted VRR (β = − 0.237; p = 0.014), while energy density (kcal/mL) predicted RFA efficacy (β = 1.416; p = 0.047). All adverse events were mild and transient, including local pain (27.5%), transient dysphonia (6.7%), and transient cough or vagal reaction. No permanent complications occurred. Conclusion PEI and RFA are safe and effective minimally invasive options for BTN, achieving durable volume reduction with improved clinical outcomes. Smaller nodules and higher energy delivery/ml predict optimal response.
- Open Access
- 26 July 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (10) , 9304-9316
Efficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight ( SUSTAIN OPTIMIZE )
Aims: Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlar reduced ) versus dose‐titrated IGlar (IGlar titrated ) on glycated haemoglobin (HbA 1c ), body weight (BW), daily insulin dose, and participant satisfaction. Materials and Methods: SUSTAIN OPTIMIZE was a 40‐week, phase 3b, open‐label, randomised study. Adults with T2D, overweight (body mass index ≥ 25 kg/m 2 ), and treatment with basal insulin ≤ 40 units/day were randomised 1:1 into Sema+IGlar reduced or IGlar titrated . The primary endpoint was change in HbA 1c using a non‐inferiority approach. Secondary endpoints assessed superiority of Sema+IGlar reduced versus IGlar titrated in reducing HbA 1c , BW, daily insulin dose, and improving Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) scores. Results: Overall, 573 participants were randomised. Sema+IGlar reduced achieved both non‐inferiority and superiority versus IGlar titrated in HbA 1c reduction (estimated treatment difference [ETD]: −0.74%; 95% confidence interval [CI 95 ]: −0.90, −0.59) and superiority in BW change (ETD: −8.5 kg; CI 95 : −9.5, −7.4), relative daily insulin dose change (ETD: −121.9%; CI 95 : −143.1, −100.6), and DTSQc scores (ETD: 2.6; CI 95 : 1.6, 3.5) ( p < 0.0001 for all endpoints). No new safety concerns were identified. Severe hypoglycaemia was reduced (rate ratio: 0.45; CI 95 : 0.23, 0.87; p = 0.02), while gastrointestinal events were higher for Sema+IGlar reduced (310 vs. 32 events). Conclusions: Once‐weekly subcutaneous semaglutide 2.0 mg as add‐on to dose‐reduced IGlar achieved superior reductions in HbA 1c , BW, and daily insulin dose in people with T2D and overweight, while reducing their risk for severe hypoglycaemia compared to dose‐titrated IGlar alone.
- 26 July 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (10) , 9304-9316
Open AccessEfficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight ( SUSTAIN OPTIMIZE )
Aims: Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlar reduced ) versus dose‐titrated IGlar (IGlar titrated ) on glycated haemoglobin (HbA 1c ), body weight (BW), daily insulin dose, and participant satisfaction. Materials and Methods: SUSTAIN OPTIMIZE was a 40‐week, phase 3b, open‐label, randomised study. Adults with T2D, overweight (body mass index ≥ 25 kg/m 2 ), and treatment with basal insulin ≤ 40 units/day were randomised 1:1 into Sema+IGlar reduced or IGlar titrated . The primary endpoint was change in HbA 1c using a non‐inferiority approach. Secondary endpoints assessed superiority of Sema+IGlar reduced versus IGlar titrated in reducing HbA 1c , BW, daily insulin dose, and improving Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) scores. Results: Overall, 573 participants were randomised. Sema+IGlar reduced achieved both non‐inferiority and superiority versus IGlar titrated in HbA 1c reduction (estimated treatment difference [ETD]: −0.74%; 95% confidence interval [CI 95 ]: −0.90, −0.59) and superiority in BW change (ETD: −8.5 kg; CI 95 : −9.5, −7.4), relative daily insulin dose change (ETD: −121.9%; CI 95 : −143.1, −100.6), and DTSQc scores (ETD: 2.6; CI 95 : 1.6, 3.5) ( p < 0.0001 for all endpoints). No new safety concerns were identified. Severe hypoglycaemia was reduced (rate ratio: 0.45; CI 95 : 0.23, 0.87; p = 0.02), while gastrointestinal events were higher for Sema+IGlar reduced (310 vs. 32 events). Conclusions: Once‐weekly subcutaneous semaglutide 2.0 mg as add‐on to dose‐reduced IGlar achieved superior reductions in HbA 1c , BW, and daily insulin dose in people with T2D and overweight, while reducing their risk for severe hypoglycaemia compared to dose‐titrated IGlar alone.
- Open Access
- 25 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3287
Natural Language Processing of Unstructured Healthcare Data for Predicting Heart Failure in Individuals with Type 2 Diabetes
Background/Objectives: Type 2 diabetes mellitus (T2DM) is a multisystemic disease with overlapping metabolic, renal, and cardiovascular effects. Within the Diabetic@ project, which aims to characterize individuals with T2DM using real-world data extracted from electronic health records (EHRs), this substudy sought to develop a predictive model for two-year heart failure (HF) risk. Methods: Multicenter, retrospective study including T2DM individuals across eight Spanish hospitals (2013–2018). Data were extracted exclusively from EHRs’ unstructured free text using clinical natural language processing (cNLP) and mapped to SNOMED CT. At inclusion, individuals were categorized as having or not prevalent HF (pHF). Predictive modeling was performed in non-pHF to assess two-year risk of developing HF, termed incident HF (iHF). Logistic regression (LR), decision trees, random forest, and XGBoost were compared, selecting for accuracy and interpretability. Results: Of 588,756 individuals with T2DM, 84,197 (14.3%) had pHF. Among non-pHF, 353,371 (60%) were used for model development (90.7% training, 9.3% validation). iHF occurred in 13.6% of the training set and 11.4% of the validation set. Ischemic heart disease was present in 16.2% overall, 37.9% in pHF, and 12.6% in non-pHF. Glycosylated hemoglobin data was rarely reported (<15%). LR achieved the best performance (AUC-ROC 0.73) using 27 predictors. Reduced 12- and clinically refined 9-predictor models performed similarly, with the latter implemented in a web-based tool. Conclusions: Unstructured data from EHRs enabled development of a two-year HF risk model for individuals with T2DM, underscoring the potential of cNLP for risk stratification across the cardiovascular–renal–metabolic spectrum.
- 25 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3287
Open AccessNatural Language Processing of Unstructured Healthcare Data for Predicting Heart Failure in Individuals with Type 2 Diabetes
Background/Objectives: Type 2 diabetes mellitus (T2DM) is a multisystemic disease with overlapping metabolic, renal, and cardiovascular effects. Within the Diabetic@ project, which aims to characterize individuals with T2DM using real-world data extracted from electronic health records (EHRs), this substudy sought to develop a predictive model for two-year heart failure (HF) risk. Methods: Multicenter, retrospective study including T2DM individuals across eight Spanish hospitals (2013–2018). Data were extracted exclusively from EHRs’ unstructured free text using clinical natural language processing (cNLP) and mapped to SNOMED CT. At inclusion, individuals were categorized as having or not prevalent HF (pHF). Predictive modeling was performed in non-pHF to assess two-year risk of developing HF, termed incident HF (iHF). Logistic regression (LR), decision trees, random forest, and XGBoost were compared, selecting for accuracy and interpretability. Results: Of 588,756 individuals with T2DM, 84,197 (14.3%) had pHF. Among non-pHF, 353,371 (60%) were used for model development (90.7% training, 9.3% validation). iHF occurred in 13.6% of the training set and 11.4% of the validation set. Ischemic heart disease was present in 16.2% overall, 37.9% in pHF, and 12.6% in non-pHF. Glycosylated hemoglobin data was rarely reported (<15%). LR achieved the best performance (AUC-ROC 0.73) using 27 predictors. Reduced 12- and clinically refined 9-predictor models performed similarly, with the latter implemented in a web-based tool. Conclusions: Unstructured data from EHRs enabled development of a two-year HF risk model for individuals with T2DM, underscoring the potential of cNLP for risk stratification across the cardiovascular–renal–metabolic spectrum.
- 12 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , 405-417
Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-effectiveness Analysis
Objective: The increasing incidence of thyroid nodules (TNs) raises concerns about overdiagnosis and overtreatment. This study evaluates the clinical and economic impact of KOIOS, a Food and Drug Administration-approved artificial intelligence (AI) tool for the management of TN. Methods: A retrospective analysis was conducted on 176 patients who underwent thyroid surgery between May 2022 and November 2024. Ultrasound images were evaluated independently by an expert and novice operators using the American College of Radiology Thyroid Imaging Reporting and Data System, while KOIOS provided AI-adapted risk stratification. Sensitivity, specificity, and receiver operating (ROC) curve analysis were performed. The incremental cost-effectiveness ratio (ICER) was defined based on the number of optimal care interventions (fine-needle aspiration biopsies and thyroid surgeries). Both deterministic and probabilistic sensitivity analyses were conducted to evaluate model robustness. Results: KOIOS AI demonstrated similar diagnostic performance to the expert operator [area under the curve (AUC): 0.794, 95% confidence interval (CI): 0.718-0.871 vs 0.784, 95% CI: 0.706-0.861; P = .754] and significantly outperformed the novice operator (AUC: 0.619, 95% CI: 0.526-0.711; P < .001). ICER analysis estimated the cost per additional optimal care decision at −€8085.56, indicating KOIOS as a dominant and cost-saving strategy when considering a third-party payer perspective over a 1-year horizon. Deterministic sensitivity analysis identified surgical costs as the main drivers of variability, while probabilistic analysis consistently favored KOIOS as the optimal strategy. Conclusion: KOIOS AI is a cost-effective alternative, particularly in reducing overdiagnosis and overtreatment for benign TNs. Prospective, real-life studies are needed to validate these findings and explore long-term implications.
- 12 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , 405-417
Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-effectiveness Analysis
Objective: The increasing incidence of thyroid nodules (TNs) raises concerns about overdiagnosis and overtreatment. This study evaluates the clinical and economic impact of KOIOS, a Food and Drug Administration-approved artificial intelligence (AI) tool for the management of TN. Methods: A retrospective analysis was conducted on 176 patients who underwent thyroid surgery between May 2022 and November 2024. Ultrasound images were evaluated independently by an expert and novice operators using the American College of Radiology Thyroid Imaging Reporting and Data System, while KOIOS provided AI-adapted risk stratification. Sensitivity, specificity, and receiver operating (ROC) curve analysis were performed. The incremental cost-effectiveness ratio (ICER) was defined based on the number of optimal care interventions (fine-needle aspiration biopsies and thyroid surgeries). Both deterministic and probabilistic sensitivity analyses were conducted to evaluate model robustness. Results: KOIOS AI demonstrated similar diagnostic performance to the expert operator [area under the curve (AUC): 0.794, 95% confidence interval (CI): 0.718-0.871 vs 0.784, 95% CI: 0.706-0.861; P = .754] and significantly outperformed the novice operator (AUC: 0.619, 95% CI: 0.526-0.711; P < .001). ICER analysis estimated the cost per additional optimal care decision at −€8085.56, indicating KOIOS as a dominant and cost-saving strategy when considering a third-party payer perspective over a 1-year horizon. Deterministic sensitivity analysis identified surgical costs as the main drivers of variability, while probabilistic analysis consistently favored KOIOS as the optimal strategy. Conclusion: KOIOS AI is a cost-effective alternative, particularly in reducing overdiagnosis and overtreatment for benign TNs. Prospective, real-life studies are needed to validate these findings and explore long-term implications.
- Open Access
- 30 November 2023
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 16 (4) , 380-387
Ultrasound-Guided Ethanol Percutaneous Ablation Versus Rescue Surgery in Patients With Locoregional Recurrence of Papillary Thyroid Cancer
Objectives Neck recurrence of papillary thyroid cancer (PTC) is frequently detected after initial surgery. The management of these lesions may include rescue surgery (RS) or minimally invasive techniques in selected patients, but comparative studies evaluating the effectiveness and safety of these techniques are lacking. In this paper, we compared ultrasound-guided ethanol ablation (EA) in selected patients to RS in a matched cohort.Methods We retrospectively compared 41 patients and 41 matched PTC patients without known distant metastases, who underwent ultrasound-guided EA or RS (matched reference group), who had 63 and 75 thyroid bed and/or lymph node confirmed PTC recurrences during a median follow-up of 72.8 and 89.6 months, respectively. The primary outcome was time until structural recurrence, compared using Kaplan-Meier survival curves. The secondary outcomes included time until biochemical recurrence, plasma thyroglobulin (Tg) levels, American Thyroid Association (ATA) response-to-therapy categories by the last available observation, and treatment-derived complications in each group.Results No significant differences were found between the EA and RS groups for time until structural recurrence (log-rank test, P=0.94). The time until biochemical recurrence was also similar (P=0.51); and the plasma Tg concentration reduction and proportions of patients in the ATA reclassification categories were also similar. A significantly higher proportion of patients in the RS group presented treatment-derived complications (29.27% vs. 9.75%, P<0.05).Conclusion In this retrospective analysis, the treatment of PTC neck recurrence with EA in selected patients was comparable to RS in a matched reference group for the long-term risk of structural or biochemical relapse, but with a lower risk of treatment-derived complications. These results support the effectiveness and safety of this minimally invasive technique in the management of selected patients with recurrent PTC.
- 30 November 2023
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Clinical and Experimental Otorhinolaryngology
- Vol. 16 (4) , 380-387
Open AccessUltrasound-Guided Ethanol Percutaneous Ablation Versus Rescue Surgery in Patients With Locoregional Recurrence of Papillary Thyroid Cancer
Objectives Neck recurrence of papillary thyroid cancer (PTC) is frequently detected after initial surgery. The management of these lesions may include rescue surgery (RS) or minimally invasive techniques in selected patients, but comparative studies evaluating the effectiveness and safety of these techniques are lacking. In this paper, we compared ultrasound-guided ethanol ablation (EA) in selected patients to RS in a matched cohort.Methods We retrospectively compared 41 patients and 41 matched PTC patients without known distant metastases, who underwent ultrasound-guided EA or RS (matched reference group), who had 63 and 75 thyroid bed and/or lymph node confirmed PTC recurrences during a median follow-up of 72.8 and 89.6 months, respectively. The primary outcome was time until structural recurrence, compared using Kaplan-Meier survival curves. The secondary outcomes included time until biochemical recurrence, plasma thyroglobulin (Tg) levels, American Thyroid Association (ATA) response-to-therapy categories by the last available observation, and treatment-derived complications in each group.Results No significant differences were found between the EA and RS groups for time until structural recurrence (log-rank test, P=0.94). The time until biochemical recurrence was also similar (P=0.51); and the plasma Tg concentration reduction and proportions of patients in the ATA reclassification categories were also similar. A significantly higher proportion of patients in the RS group presented treatment-derived complications (29.27% vs. 9.75%, P<0.05).Conclusion In this retrospective analysis, the treatment of PTC neck recurrence with EA in selected patients was comparable to RS in a matched reference group for the long-term risk of structural or biochemical relapse, but with a lower risk of treatment-derived complications. These results support the effectiveness and safety of this minimally invasive technique in the management of selected patients with recurrent PTC.
- Open Access
- 13 March 2023
- Published by Bioscientifica in European Thyroid Journal
- Vol. 12 (3)
Age-standardized incidence, mortality rate, and trend changes of thyroid cancer in the Balearic Islands during the 2000–2020 period: a population-based study
Objective: Global thyroid cancer (TC) incidence is growing worldwide, but great heterogenicity exists among published studies, and thus, population-specific epidemiological studies are needed to adequate health resources and evaluate the impact of overdiagnosis. Methods: We conducted a Public Health System database retrospective review of TC incident cases from 2000 to 2020 in the Balearic Islands region and evaluated age-standardized incidence rate (ASIR), age at diagnosis, gender distribution, tumor size and histological subtype, mortality rate (MR), and cause of death. Estimated annual percent changes (EAPCs) were also evaluated and data from the 2000–2009 period were compared to the 2010–2020 period when neck ultrasound (US) was routinely performed by clinicians at Endocrinology Departments. Results: A total of 1387 incident cases of TC were detected. Overall, ASIR (×105) was 5.01 with a 7.82% increment in EAPC. A significant increase in the 2010–2020 period was seen for ASIR (6.99 vs 2.82, P < 0.001) and age at diagnosis (52.11 vs 47.32, P < 0.001) compared to the 2000–2009 period. A reduction in tumor size (2.00 vs 2.78 cm, P < 0.001) and a 6.31% increase in micropapillary TC (P < 0.05) were also seen. Disease-specific MR remained stable at 0.21 (×105). The mean age at diagnosis for all mortality groups was older than survivors (P < 0.001). Conclusion: The incidence of TC has grown in the 2000–2020 period in the Balearic Islands, but MR has not changed. Beyond other factors, a significant contribution of overdiagnosis to this increased incidence is likely due to changes in the routine management of thyroid nodular disease and increased availability of neck US.
- 13 March 2023
- Published by Bioscientifica in European Thyroid Journal
- Vol. 12 (3)
Open AccessAge-standardized incidence, mortality rate, and trend changes of thyroid cancer in the Balearic Islands during the 2000–2020 period: a population-based study
Objective: Global thyroid cancer (TC) incidence is growing worldwide, but great heterogenicity exists among published studies, and thus, population-specific epidemiological studies are needed to adequate health resources and evaluate the impact of overdiagnosis. Methods: We conducted a Public Health System database retrospective review of TC incident cases from 2000 to 2020 in the Balearic Islands region and evaluated age-standardized incidence rate (ASIR), age at diagnosis, gender distribution, tumor size and histological subtype, mortality rate (MR), and cause of death. Estimated annual percent changes (EAPCs) were also evaluated and data from the 2000–2009 period were compared to the 2010–2020 period when neck ultrasound (US) was routinely performed by clinicians at Endocrinology Departments. Results: A total of 1387 incident cases of TC were detected. Overall, ASIR (×105) was 5.01 with a 7.82% increment in EAPC. A significant increase in the 2010–2020 period was seen for ASIR (6.99 vs 2.82, P < 0.001) and age at diagnosis (52.11 vs 47.32, P < 0.001) compared to the 2000–2009 period. A reduction in tumor size (2.00 vs 2.78 cm, P < 0.001) and a 6.31% increase in micropapillary TC (P < 0.05) were also seen. Disease-specific MR remained stable at 0.21 (×105). The mean age at diagnosis for all mortality groups was older than survivors (P < 0.001). Conclusion: The incidence of TC has grown in the 2000–2020 period in the Balearic Islands, but MR has not changed. Beyond other factors, a significant contribution of overdiagnosis to this increased incidence is likely due to changes in the routine management of thyroid nodular disease and increased availability of neck US.
- Open Access
- 1 March 2021
- Published by Elsevier in Endocrine and Metabolic Science
- Vol. 2, 100082
An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain
- 1 March 2021
- Published by Elsevier in Endocrine and Metabolic Science
- Vol. 2, 100082
Open AccessAn observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain
- Open Access
- 30 November 2020
- Published by Korean Thyroid Association in International Journal of Thyroidology
- Vol. 13 (2) , 128-141
Ultrasound-Guided Percutaneous Ethanol Ablation for the Management of Recurrent Thyroid Cancer: Evaluation of Efficacy and Impact on Disease Course
- 30 November 2020
- Published by Korean Thyroid Association in International Journal of Thyroidology
- Vol. 13 (2) , 128-141
Open AccessUltrasound-Guided Percutaneous Ethanol Ablation for the Management of Recurrent Thyroid Cancer: Evaluation of Efficacy and Impact on Disease Course
- Open Access
- 19 November 2018
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 2 (1) , e00051
Real‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study
Summary: Aims: To evaluate in a real‐world setting the effectiveness and tolerability of available GLP‐1 RA drugs in patients with type 2 diabetes after a prolonged follow‐up.Materials and methods: Observational, retrospective, single‐centre study in patients starting GLP‐1 RA therapy. Change in HbA1c, fasting plasma glucose (FPG) and body mass index (BMI) along with gastrointestinal (GI) adverse events and withdrawal from GLP‐1 RA therapy were evaluated. Lack of efficacy of GLP‐1 RA therapy according to prespecified goals was also measured.Results: A total of 735 patients were included, mean age 59.7 years, duration of diabetes 9.01 years, HbA1c 8.18% and BMI 38.56 kg/m2. Average follow‐up was 18.97 months (range 4.2‐39.09). All HbA1c (0.93%; P < 0.01), FPG (24 mg/dL; P < 0.01) and BMI (1.55 kg/m2; P < 0.05) were significantly reduced from baseline and maintained throughout follow‐up, regardless of prescribed GLP‐1 RA. GI adverse events were present in 13.81% of patients at first follow‐up visit, 37.07% of patients discontinued GLP‐1 RA treatment, and 38.63% did not meet efficacy goals.Conclusions: In a real‐world setting, GLP‐1 RA therapy is largely prescribed in severely obese patients with a long‐standing and poorly controlled diabetes. All prescribed GLP‐1 RAs significantly decreased HbA1c, FPG and BMI. GI adverse events affected a low proportion of patients. Inversely, a high proportion of patients did not meet efficacy goals and/or discontinued GLP‐1 RA treatment. Baseline characteristics of patients and lack of adherence may represent important issues underlying differences in effectiveness in real‐world studies versus randomized trials.
- 19 November 2018
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 2 (1) , e00051
Open AccessReal‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study
Summary: Aims: To evaluate in a real‐world setting the effectiveness and tolerability of available GLP‐1 RA drugs in patients with type 2 diabetes after a prolonged follow‐up.Materials and methods: Observational, retrospective, single‐centre study in patients starting GLP‐1 RA therapy. Change in HbA1c, fasting plasma glucose (FPG) and body mass index (BMI) along with gastrointestinal (GI) adverse events and withdrawal from GLP‐1 RA therapy were evaluated. Lack of efficacy of GLP‐1 RA therapy according to prespecified goals was also measured.Results: A total of 735 patients were included, mean age 59.7 years, duration of diabetes 9.01 years, HbA1c 8.18% and BMI 38.56 kg/m2. Average follow‐up was 18.97 months (range 4.2‐39.09). All HbA1c (0.93%; P < 0.01), FPG (24 mg/dL; P < 0.01) and BMI (1.55 kg/m2; P < 0.05) were significantly reduced from baseline and maintained throughout follow‐up, regardless of prescribed GLP‐1 RA. GI adverse events were present in 13.81% of patients at first follow‐up visit, 37.07% of patients discontinued GLP‐1 RA treatment, and 38.63% did not meet efficacy goals.Conclusions: In a real‐world setting, GLP‐1 RA therapy is largely prescribed in severely obese patients with a long‐standing and poorly controlled diabetes. All prescribed GLP‐1 RAs significantly decreased HbA1c, FPG and BMI. GI adverse events affected a low proportion of patients. Inversely, a high proportion of patients did not meet efficacy goals and/or discontinued GLP‐1 RA treatment. Baseline characteristics of patients and lack of adherence may represent important issues underlying differences in effectiveness in real‐world studies versus randomized trials.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Male hypogonadism due to 46, XX Testicular disorder of sex development
Introduction: 46,XX testicular disorder of sex development (DSD) is a rare syndrome, which is characterized by a female karyotype in discordance with a male phenotype. It is presented with primary hypogonadism, gynecomastia and infertility. About 80–90% of 46,XX testicular DSD cases are positive for SRY gene. Appearance of external genitalia and masculinization are usually normal in 46,XX SRY-positive cases Clinical case: A 41-year-old male came with his partner to the outpatient clinic because of low levels of testosterone detected in routine blood test. He complained about fatigue, low libido and some difficulties to maintain erections since one year. He had no history of mumps, trauma or surgery.He was 169 cm tall and he weighted 74 kg, BMI of 25.9 kg/m2. The physical examination reveled a normal penis size, with small soft testis (2 ml). No gynecomastia was detected. Facial, body, and pubic hair were of normal density and distribution. He related his small size of testis since puberty. He had not consulted before for this Laboratoy test showed a low level of total and free testosterone, high levels of gonadotropins, normal levels of prolactin and estrogens. A karyotype and semen analysis were assessed. The karyotype analysis showed a 46,XX formula. The polymerase chain reaction analysis confirmed the presence of SRY gen. The semen analysis showed azoospermia. These results were consistent with 46, XX DSD. The diagnostic had a high emotional impact and he needed psychological support to accepted it and the fact that he was infertile He started testosterone replacement but he refused to do other tests: magnetic resonance imaging of the pelvis or bone densitometry. Conclusion: It is important to diagnose as soon as possible this testicular DSD syndrome, to avoid its negative emotional impact and the consequences of a chronic testosterone deficiency.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Male hypogonadism due to 46, XX Testicular disorder of sex development
Introduction: 46,XX testicular disorder of sex development (DSD) is a rare syndrome, which is characterized by a female karyotype in discordance with a male phenotype. It is presented with primary hypogonadism, gynecomastia and infertility. About 80–90% of 46,XX testicular DSD cases are positive for SRY gene. Appearance of external genitalia and masculinization are usually normal in 46,XX SRY-positive cases Clinical case: A 41-year-old male came with his partner to the outpatient clinic because of low levels of testosterone detected in routine blood test. He complained about fatigue, low libido and some difficulties to maintain erections since one year. He had no history of mumps, trauma or surgery.He was 169 cm tall and he weighted 74 kg, BMI of 25.9 kg/m2. The physical examination reveled a normal penis size, with small soft testis (2 ml). No gynecomastia was detected. Facial, body, and pubic hair were of normal density and distribution. He related his small size of testis since puberty. He had not consulted before for this Laboratoy test showed a low level of total and free testosterone, high levels of gonadotropins, normal levels of prolactin and estrogens. A karyotype and semen analysis were assessed. The karyotype analysis showed a 46,XX formula. The polymerase chain reaction analysis confirmed the presence of SRY gen. The semen analysis showed azoospermia. These results were consistent with 46, XX DSD. The diagnostic had a high emotional impact and he needed psychological support to accepted it and the fact that he was infertile He started testosterone replacement but he refused to do other tests: magnetic resonance imaging of the pelvis or bone densitometry. Conclusion: It is important to diagnose as soon as possible this testicular DSD syndrome, to avoid its negative emotional impact and the consequences of a chronic testosterone deficiency.